Related Experiment Video
Updated: Dec 29, 2025

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images
Published on: September 7, 2017
ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression
Qingyu Luo1, Xiaowei Wu1, Wan Chang1
1State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract:
Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complexes have a mutation rate of approximately 20% in human cancer, and ARID1A is the most frequently mutated component. However, some components of SWI/SNF complexes, including ARID1A, exhibit a very low mutation rate in squamous cell carcinoma (SCC), and their role in SCC remains unknown. Here, we demonstrate that the low expression of ARID1A in SCC is the result of promoter hypermethylation. Low levels of ARID1A were associated with a poor prognosis. ARID1A maintained transcriptional homeostasis through both direct and indirect chromatin-remodeling mechanisms. Depletion of ARID1A activated an oncogenic transcriptome that drove SCC progression. The anti-inflammatory natural product parthenolide was synthetically lethal to ARID1A-depleted SCC cells due to its inhibition of both HDAC1 and oncogenic signaling. These findings support the clinical application of parthenolide to treat patients with SCC with low ARID1A expression. SIGNIFICANCE: This study reveals novel inactivation mechanisms and tumor-suppressive roles of ARID1A in SCC and proposes parthenolide as an effective treatment for patients with SCC with low ARID1A expression.
Insights
ARID1A deficiency in squamous cell carcinoma (SCC) is caused by promoter hypermethylation, leading to poor prognosis. Parthenolide effectively targets ARID1A-depleted SCC cells, suggesting a new treatment strategy.
Area of Science:
- Oncology
- Epigenetics
- Chromatin Biology
Background:
- Switch/Sucrose Non-Fermentable (SWI/SNF) complexes are frequently mutated in cancer.
- ARID1A, a key SWI/SNF component, has low mutation rates but unknown roles in squamous cell carcinoma (SCC).
Purpose of the Study:
- Investigate ARID1A's role and inactivation mechanisms in SCC.
- Identify therapeutic strategies for ARID1A-deficient SCC.
Main Methods:
- Analysis of ARID1A expression and promoter methylation in SCC.
- Functional studies involving ARID1A depletion and transcriptome analysis.
- Evaluation of parthenolide's efficacy in ARID1A-depleted SCC cells.
Main Results:
- ARID1A is downregulated in SCC due to promoter hypermethylation, correlating with poor prognosis.
- ARID1A depletion activates an oncogenic transcriptome, promoting SCC progression.
- Parthenolide exhibits synthetic lethality in ARID1A-depleted SCC cells by inhibiting HDAC1 and oncogenic signaling.
Conclusions:
- ARID1A functions as a tumor suppressor in SCC through chromatin remodeling.
- Promoter hypermethylation is a key mechanism of ARID1A inactivation in SCC.
- Parthenolide represents a promising therapeutic agent for ARID1A-low SCC.
More Related Videos
13:47Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution
Published on: February 24, 2015
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
MicroRNAs